Revisión bibliográfica de terapia CAR T: enfoque en los diferentes sistemas de entrega novedosos

Reina Quiñones, Valentina; Rivera Otalora, María Valentina

Revisión bibliográfica de terapia CAR T: enfoque en los diferentes sistemas de entrega novedosos

dc.contributor.advisor	Velandia Paris, María Angélica
dc.contributor.author	Reina Quiñones, Valentina
dc.contributor.author	Rivera Otalora, María Valentina
dc.date.accessioned	2024-11-20T20:01:11Z
dc.date.available	2024-11-20T20:01:11Z
dc.date.issued	2024-10
dc.description.abstract	La terapia adaptativa de células T (CAR-T) ha revolucionado el tratamiento de la inmunoterapia contra el cáncer la cual consiste en modificar genéticamente las células T del paciente con los receptores quiméricos CAR para obtener un reconocimiento específico frente a células cancerígenas, sin embargo, esta terapia presenta obstáculos relacionados con la toxicidad, el microambiente tumoral, persistencia terapéutica, biocompatibilidad e infiltración. Esta revisión bibliográfica basada en el método PRISMA tiene como objetivo evaluar los diferentes sistemas de entrega novedosos de las terapias CAR-T en función de su relevancia terapéutica en contraste con el sistema de entrega convencional, para evaluar los diferentes sistemas de entrega novedosos, principalmente los exosomas, sistemas inorgánicos, NP poliméricas y lipídicas; si bien cada sistema presenta características únicas, la investigación actual apunta hacia la combinación de estas tecnologías para crear sistemas de entrega híbridos, que maximicen los beneficios. Esta sinergia biofarmacéutica podría revolucionar la terapia CAR-T, ampliando su eficacia, seguridad y accesibilidad. No obstante, persisten desafíos que requieren investigación continua. El desarrollo de nuevas estrategias, como la combinación con otros tratamientos y la optimización de los sistemas de entrega mediante biotecnología.
dc.description.abstractenglish	Adaptive T-cell therapy (CAR-T) has revolutionized the treatment of cancer immunotherapy. cancer immunotherapy, which consists of genetically modifying the patient's T-cells with chimeric CAR receptors to obtain specific CAR chimeric receptors to obtain specific recognition against cancer cells. However, this therapy presents obstacles related to toxicity, the tumor microenvironment, persistence and tumor microenvironment, therapeutic persistence, biocompatibility and infiltration. This literature This literature review based on the PRISMA method aims to evaluate the different novel delivery systems of novel delivery systems of CAR-T therapies in terms of their therapeutic relevance in contrast to the conventional delivery system, to evaluate the the conventional delivery system, to evaluate the different novel delivery systems, mainly exosomes, inorganic systems, polymeric and lipidic NPs; while each system has unique characteristics, current research is unique characteristics, current research points towards the combination of these technologies to create hybrid technologies to create hybrid delivery systems that maximize benefits. This biopharmaceutical This biopharmaceutical synergy could revolutionize CAR-T therapy, expanding its efficacy, safety and accessibility. accessibility. However, challenges remain that require continued research. The development of new new strategies, such as combination with other treatments and optimization of delivery systems through biotechnology. delivery systems through biotechnology.
dc.description.degreelevel	Pregrado	spa
dc.description.degreelevel	Químico Farmacéutico	spa
dc.format.mimetype	application/pdf
dc.identifier.instname	Universidad El Bosque	spa
dc.identifier.reponame	reponame:Repositorio Institucional Universidad El Bosque	spa
dc.identifier.repourl	repourl:https://repositorio.unbosque.edu.co
dc.identifier.uri	https://hdl.handle.net/20.500.12495/13280
dc.language.iso	es
dc.publisher.faculty	Facultad de Ciencias	spa
dc.publisher.grantor	Universidad El Bosque	spa
dc.publisher.program	Química Farmacéutica	spa
dc.relation.references	Cáncer Available online: https://www.who.int/es/news-room/fact-sheets/detail/cancer (accessed on 18 September 2024).
dc.relation.references	Siegel, R.L.; Miller, K.D.; Wagle, N.S.; Jemal, A. Cancer Statistics, 2023. CA Cancer J Clin 2023, 73, 17–48, doi:10.3322/caac.21763.
dc.relation.references	Cómo Se Usa La Inmunoterapia Para Tratar El Cáncer; Available online: https://www.cancer.org/es/cancer/como-sobrellevar-el-cancer/tipos-de-tratamiento/inmunoterapia/como-se-usa-la-inmunoterapia.html (accessed on 18 September 2024).
dc.relation.references	Atsavapranee, E.S.; Billingsley, M.M.; Mitchell, M.J. Delivery Technologies for T Cell Gene Editing: Applications in Cancer Immunotherapy. EBioMedicine 2021, 67.
dc.relation.references	Terapia de Células CAR-T y Sus Efectos Secundarios Available online: https://www.cancer.org/es/cancer/como-sobrellevar-el-cancer/tipos-de-tratamiento/inmunoterapia/terapia- de-celulas-t.html (accessed on 18 September 2024).
dc.relation.references	Shan, X.; Gong, X.; Li, J.; Wen, J.; Li, Y.; Zhang, Z. Current Approaches of Nanomedicines in the Market and Various Stage of Clinical Translation. Acta Pharm Sin B 2022, 12, 3028–3048.
dc.relation.references	Xie, X.; Zhang, J.; Wang, Y.; Shi, W.; Tang, R.; Tang, Q.; Sun, S.; Wu, R.; Xu, S.; Wang, M.; et al. Nanomaterials Augmented Bioeffects of Ultrasound in Cancer Immunotherapy. Mater Today Bio 2024, 24.
dc.relation.references	Xiao, Q.; Li, X.; Li, Y.; Wu, Z.; Xu, C.; Chen, Z.; He, W. Biological Drug and Drug Delivery-Mediated Immunotherapy. Acta Pharm Sin B 2021, 11, 941–960.
dc.relation.references	Drug Delivery Systems Available online: https://www.nibib.nih.gov/science-education/science-topics/drug- delivery-systems-getting-drugs-their-targets-controlled-manner (accessed on 18 September 2024).
dc.relation.references	PubMed: guía básica tesauros MESH Available online: https://biblioguias.ucm.es/med-pubmed/tesauro (accessed on 9 june 2023)
dc.relation.references	Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews. The BMJ 2021, 372.
dc.relation.references	Cauchon, N.S.; Oghamian, S.; Hassanpour, S.; Abernathy, M. Innovation in Chemistry, Manufacturing, and Controls—A Regulatory Perspective From Industry. J Pharm Sci 2019, 108, 2207–2237.
dc.relation.references	Zhang, Y.; Li, Y.; Cao, W.; Wang, F.; Xie, X.; Li, Y.; Wang, X.; Guo, R.; Jiang, Z.; Guo, R. Single-Cell Analysis of Target Antigens of CAR-T Reveals a Potential Landscape of “On-Target, Off-Tumor Toxicity.” Front Immunol 2021, 12, doi:10.3389/FIMMU.2021.799206/FULL.
dc.relation.references	Sánchez-Escamilla, M.; Yáñez San Segundo, L.; Urbano-Ispizua, Á.; Perales, M.Á. CAR T Cells: The Future Is Already Present. Med Clin (Barc) 2019, 152, 281–286, doi:10.1016/j.medcli.2018.08.015.
dc.relation.references	Tipos de Trasplantes de Células Madre y Médula Ósea Available online: https://www.cancer.org/es/cancer/como-sobrellevar-el-cancer/tipos-de-tratamiento/trasplante-de-celulas- madre/tipos-de-trasplantes.html (accessed on 18 September 2024).
dc.relation.references	Terapia de Células CAR-T y Sus Efectos Secundarios Available online: https://www.cancer.org/es/cancer/como-sobrellevar-el-cancer/tipos-de-tratamiento/inmunoterapia/terapia- de-celulas-t.html# (accessed on 18 September 2024).
dc.relation.references	Korell, F.; Berger, T.R.; Maus, M. V. Understanding CAR T Cell-Tumor Interactions: Paving the Way for Successful Clinical Outcomes. Med 2022, 3, 538–564.
dc.relation.references	Alnefaie, A.; Albogami, S.; Asiri, Y.; Ahmad, T.; Alotaibi, S.S.; Al-Sanea, M.M.; Althobaiti, H. Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions. Front Bioeng Biotechnol 2022, 10.
dc.relation.references	Benmebarek, M.R.; Karches, C.H.; Cadilha, B.L.; Lesch, S.; Endres, S.; Kobold, S. Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells. Int J Mol Sci 2019, 20.
dc.relation.references	Chen, X.; Xu, Z.; Li, T.; Thakur, A.; Wen, Y.; Zhang, K.; Liu, Y.; Liang, Q.; Liu, W.; Qin, J.J.; et al. Nanomaterial- Encapsulated STING Agonists for Immune Modulation in Cancer Therapy. Biomark Res 2024, 12.
dc.relation.references	Zhu, Y.H.; Zheng, J.H.; Jia, Q.Y.; Duan, Z.H.; Yao, H.F.; Yang, J.; Sun, Y.W.; Jiang, S.H.; Liu, D.J.; Huo, Y.M. Immunosuppression, Immune Escape, and Immunotherapy in Pancreatic Cancer: Focused on the Tumor Microenvironment. Cellular Oncology 2023, 46, 17–48.
dc.relation.references	Fernandes, Q.; Therachiyil, L.; Khan, A.Q.; Bedhiafi, T.; Korashy, H.M.; Bhat, A.A.; Uddin, S. Shrinking the Battlefield in Cancer Therapy: Nanotechnology against Cancer Stem Cells. European Journal of Pharmaceutical Sciences 2023, 191, doi:10.1016/j.ejps.2023.106586.
dc.relation.references	Efectos Secundarios de La Quimioterapia Available online: https://www.cancer.org/es/cancer/como- sobrellevar-el-cancer/tipos-de tratamiento/quimioterapia/efectos-secundarios-de-la-quimioterapia.html (accessed on 18 September 2024).
dc.relation.references	Gu, X.; Zhang, Y.; Zhou, W.; Wang, F.; Yan, F.; Gao, H.; Wang, W. Infusion and Delivery Strategies to Maximize the Efficacy of CAR-T Cell Immunotherapy for Cancers. Exp Hematol Oncol 2024, 13, 70, doi:10.1186/s40164- 024-00542-2.
dc.relation.references	:: .:: CIMA ::. FICHA TECNICA YESCARTA 0,4 - 2 x 10e8 CELULAS DISPERSION PARA PERFUSION Available online: https://cima.aemps.es/cima/dochtml/ft/1181299001/FT_1181299001.html (accessed on 4 November 2024).
dc.relation.references	Drug Delivery Systems Available online: https://www.nibib.nih.gov/science-education/science-topics/drug- delivery-systems-getting-drugs-their-targets-controlled-manner (accessed on 4 November 2024).
dc.relation.references	Roddie, C.; O’Reilly, M.; Dias Alves Pinto, J.; Vispute, K.; Lowdell, M. Manufacturing Chimeric Antigen Receptor T Cells: Issues and Challenges. Cytotherapy 2019, 21, 327–340, doi:10.1016/j.jcyt.2018.11.009.
dc.relation.references	Hu, D.; Zhang, W.; Tang, J.; Zhou, Z.; Liu, X.; Shen, Y. Improving Safety of Cancer Immunotherapy via Delivery Technology. Biomaterials 2021, 265.
dc.relation.references	Pinto, I.S.; Cordeiro, R.A.; Faneca, H. Polymer- and Lipid-Based Gene Delivery Technology for CAR T Cell Therapy. Journal of Controlled Release 2023, 353, 196–215.
dc.relation.references	Rahimi, A.; Esmaeili, Y.; Dana, N.; Dabiri, A.; Rahimmanesh, I.; Jandaghian, S.; Vaseghi, G.; Shariati, L.; Zarrabi, A.; Haghjooy Javanmard, S.; et al. A Comprehensive Review on Novel Targeted Therapy Methods and Nanotechnology-Based Gene Delivery Systems in Melanoma. European Journal of Pharmaceutical Sciences 2023, 187, doi:10.1016/j.ejps.2023.106476.
dc.relation.references	Estapé Senti, M.; García del Valle, L.; Schiffelers, R.M. MRNA Delivery Systems for Cancer Immunotherapy: Lipid Nanoparticles and Beyond. Adv Drug Deliv Rev 2024, 206.
dc.relation.references	Pondman, K.; Le Gac, S.; Kishore, U. Nanoparticle-Induced Immune Response: Health Risk versus Treatment Opportunity? Immunobiology 2023, 228, doi:10.1016/j.imbio.2022.152317.
dc.relation.references	Alhamhoom, Y.; Kakinani, G.; Rahamathulla, M.; Ali M. Osmani, R.; Hani, U.; Yoonus Thajudeen, K.; Kiran Raj, G.; Gowda, D. V. Recent Advances in the Liposomal Nanovesicles Based Immunotherapy in the Treatment of Cancer: A Review. Saudi Pharmaceutical Journal 2023, 31, 279–294.
dc.relation.references	Billingsley, M.M.; Singh, N.; Ravikumar, P.; Zhang, R.; June, C.H.; Mitchell, M.J. Ionizable Lipid Nanoparticle- Mediated MRNA Delivery for Human CAR T Cell Engineering. Nano Lett 2020, 20, 1578–1589, doi:10.1021/acs.nanolett.9b04246.
dc.relation.references	Zhang, X.; Jin, X.; Sun, R.; Zhang, M.; Lu, W.; Zhao, M. Gene Knockout in Cellular Immunotherapy: Application and Limitations. Cancer Lett 2022, 540.
dc.relation.references	Rhym, L.H.; Anderson, D.G. Nanoscale Delivery Platforms for RNA Therapeutics: Challenges and the Current State of the Art. Med 2022, 3, 167–187.
dc.relation.references	Huang, G.; Tang, Z.; Yin, T.; Ma, A.; Gong, H.; Zhang, Y.; Pan, H.; Cai, L. Bioactive-Material-Programmed CAR- T Cell Living Drug for Augmented Immunotherapy against Tumors. Cell Rep Phys Sci 2024, 5.
dc.relation.references	Xie, Z.; Shen, J.; Sun, H.; Li, J.; Wang, X. Polymer-Based Hydrogels with Local Drug Release for Cancer Immunotherapy. Biomedicine and Pharmacotherapy 2021, 137.
dc.relation.references	Jung, I.; Shin, S.; Baek, M.C.; Yea, K. Modification of Immune Cell-Derived Exosomes for Enhanced Cancer Immunotherapy: Current Advances and Therapeutic Applications. Exp Mol Med 2024, 56, 19–31.
dc.relation.references	Yan, W.; Jiang, S. Immune Cell-Derived Exosomes in the Cancer-Immunity Cycle. Trends Cancer 2020, 6, 506– 517.
dc.relation.references	Yang, Q.; Li, S.; Ou, H.; Zhang, Y.; Zhu, G.; Li, S.; Lei, L. Exosome-Based Delivery Strategies for Tumor Therapy: An Update on Modification, Loading, and Clinical Application. J Nanobiotechnology 2024, 22.
dc.relation.references	De La Peña, H.; Madrigal, J.A.; Rusakiewicz, S.; Bencsik, M.; Cave, G.W.V.; Selman, A.; Rees, R.C.; Travers, P.J.; Dodi, I.A. Artificial Exosomes as Tools for Basic and Clinical Immunology. J Immunol Methods 2009, 344, 121– 132, doi:10.1016/j.jim.2009.03.011.
dc.relation.references	Chen, J.; Tan, Q.; Yang, Z.; Jin, Y. Engineered Extracellular Vesicles: Potentials in Cancer Combination Therapy. J Nanobiotechnology 2022, 20.
dc.relation.references	Lei, W.; Yang, C.; Wu, Y.; Ru, G.; He, X.; Tong, X.; Wang, S. Nanocarriers Surface Engineered with Cell Membranes for Cancer Targeted Chemotherapy. J Nanobiotechnology 2022, 20.
dc.relation.references	Chen, H.Y.; Deng, J.; Wang, Y.; Wu, C.Q.; Li, X.; Dai, H.W. Hybrid Cell Membrane-Coated Nanoparticles: A Multifunctional Biomimetic Platform for Cancer Diagnosis and Therapy. Acta Biomater 2020, 112, 1–13.
dc.relation.references	Sahu, B.P.; Baishya, R.; Hatiboruah, J.L.; Laloo, D.; Biswas, N. A Comprehensive Review on Different Approaches for Tumor Targeting Using Nanocarriers and Recent Developments with Special Focus on Multifunctional Approaches. J Pharm Investig 2022, 52, 539–585.
dc.relation.references	Sun, N.; Zhao, L.; Zhu, J.; Li, Y.; Song, N.; Xing, Y.; Qiao, W.; Huang, H.; Zhao, J. 131i-Labeled Polyethylenimine-Entrapped Gold Nanoparticles for Targeted Tumor Spect/Ct Imaging and Radionuclide Therapy. Int J Nanomedicine 2019, 14, 4367–4381, doi:10.2147/IJN.S203259.
dc.relation.references	Senapati, S.; Mahanta, A.K.; Kumar, S.; Maiti, P. Controlled Drug Delivery Vehicles for Cancer Treatment and Their Performance. Signal Transduct Target Ther 2018, 3.
dc.relation.references	Kang, W.; Liu, Y.; Wang, W. Light-Responsive Nanomedicine for Cancer Immunotherapy. Acta Pharm Sin B 2023, 13, 2346–2368.
dc.relation.references	Schneider-Futschik, E.K.; Reyes-Ortega, F. Pharmaceutics Advantages and Disadvantages of Using Magnetic Nanoparticles for the Treatment of Complicated Ocular Disorders. 2021, doi:10.3390/pharmaceutics.
dc.relation.references	Nakamura, T.; Miyabe, H.; Hyodo, M.; Sato, Y.; Hayakawa, Y.; Harashima, H. Liposomes Loaded with a STING Pathway Ligand, Cyclic Di-GMP, Enhance Cancer Immunotherapy against Metastatic Melanoma. Journal of Controlled Release 2015, 216, 149–157, doi:10.1016/j.jconrel.2015.08.026.
dc.relation.references	Shin, H.E.; Han, J.-H.; Shin, S.; Bae, G.-H.; Son, B.; Kim, T.-H.; Park, H.H.; Park, C.G.; Park, W. M1-Polarized Macrophage-Derived Cellular Nanovesicle-Coated Lipid Nanoparticles for Enhanced Cancer Treatment through Hybridization of Gene Therapy and Cancer Immunotherapy. Acta Pharm Sin B 2024, doi:10.1016/j.apsb.2024.03.004.
dc.relation.references	Tarlatamab Para El Cáncer de Pulmón de Células Pequeñas Available online: https://www.cancer.gov/espanol/noticias/temas-y-relatos-blog/2024/tarlatamab-cancer-pulmon-de-celulas- pequenas (accessed on 18 September 2024).
dc.relation.references	Zhao, Y.; Wang, Q.J.; Yang, S.; Kochenderfer, J.N.; Zheng, Z.; Zhong, X.; Sadelain, M.; Eshhar, Z.; Rosenberg, S.A.; Morgan, R.A. A Herceptin-Based Chimeric Antigen Receptor with Modified Signaling Domains Leads to Enhanced Survival of Transduced T Lymphocytes and Antitumor Activity. J Immunol 2009, 183, 5563–5574, doi:10.4049/JIMMUNOL.0900447.
dc.relation.references	Kane, G.I.; Lusi, C.F.; Brassil, M.L.; Atukorale, P.U. Engineering Approaches for Innate Immune-Mediated Tumor Microenvironment Remodeling. Immuno-Oncology and Technology 2024, 21.
dc.relation.references	Gong, Y.; Klein Wolterink, R.G.J.; Wang, J.; Bos, G.M.J.; Germeraad, W.T.V. Chimeric Antigen Receptor Natural Killer (CAR-NK) Cell Design and Engineering for Cancer Therapy. J Hematol Oncol 2021, 14.
dc.relation.references	Liu, S.; Wei, W.; Wang, J.; Chen, T. Theranostic Applications of Selenium Nanomedicines against Lung Cancer. Journal of Nanobiotechnology 2023 21:1 2023, 21, 1–35, doi:10.1186/S12951-023-01825-2.
dc.relation.references	Hossian, A.K.M.N.; Hackett, C.S.; Brentjens, R.J.; Rafiq, S. Multipurposing CARs: Same Engine, Different Vehicles. Molecular Therapy 2022, 30, 1381–1395.
dc.relation.references	Vitanza, N.A.; Johnson, A.J.; Wilson, A.L.; Brown, C.; Yokoyama, J.K.; Künkele, A.; Chang, C.A.; Rawlings- Rhea, S.; Huang, W.; Seidel, K.; et al. Locoregional Infusion of HER2-Specific CAR T Cells in Children and Young Adults with Recurrent or Refractory CNS Tumors: An Interim Analysis. Nat Med 2021, 27, 1544–1552, doi:10.1038/s41591-021-01404-8.
dc.relation.references	DiNofia, A.M.; Grupp, S.A. Will Allogeneic CAR T Cells for CD19+ Malignancies Take Autologous CAR T Cells ‘off the Shelf’? Nat Rev Clin Oncol 2021, 18, 195–196.
dc.relation.references	CAR-T Cell - Inmunoterapia Prometedora Contra El Cáncer - CONSULTORSALUD Available online: https://consultorsalud.com/car-t-cell-inmunoterapia-contra-el-cancer/ (accessed on 18 September 2024).
dc.relation.references	Sun, W.; Jiang, Z.; Jiang, W.; Yang, R. Universal Chimeric Antigen Receptor T Cell Therapy — The Future of Cell Therapy: A Review Providing Clinical Evidence. Cancer Treat Res Commun 2022, 33.
dc.relation.references	Grupp, S.A.; Maude, S.L.; Rives, S.; Baruchel, A.; Boyer, M.W.; Bittencourt, H.; Bader, P.; Büchner, J.; Laetsch, T.W.; Stefanski, H.; et al. Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia. Blood 2018, 132, 895, doi:10.1182/BLOOD-2018-99-112599.
dc.relation.references	Huang, Y.; Fan, H.; Ti, H. Tumor Microenvironment Reprogramming by Nanomedicine to Enhance the Effect of Tumor Immunotherapy. Asian J Pharm Sci 2024, 100902, doi:10.1016/j.ajps.2024.100902.
dc.relation.references	Pacheco, C.; Baião, A.; Ding, T.; Cui, W.; Sarmento, B. Recent Advances in Long-Acting Drug Delivery Systems for Anticancer Drug. Adv Drug Deliv Rev 2023, 194.
dc.relation.references	Khawar, M.B.; Afzal, A.; Abbasi, M.H.; Sheikh, N.; Sun, H. Nano-Immunoengineering of CAR-T Cell Therapy against Tumor Microenvironment: The Way Forward in Combating Cancer. OpenNano 2023, 10, doi:10.1016/j.onano.2023.100124.
dc.relation.references	Wu, X.; Matosevic, S. Gene-Edited and CAR-NK Cells: Opportunities and Challenges with Engineering of NK Cells for Immunotherapy. Mol Ther Oncolytics 2022, 27, 224–238.
dc.relation.references	Ulbrich, K.; Holá, K.; Šubr, V.; Bakandritsos, A.; Tuček, J.; Zbořil, R. Targeted Drug Delivery with Polymers and Magnetic Nanoparticles: Covalent and Noncovalent Approaches, Release Control, and Clinical Studies. Chem Rev 2016, 116, 5338–5431.
dc.rights	Atribución-NoComercial-CompartirIgual 4.0 Internacional
dc.rights.accessrights	info:eu-repo/semantics/openAccess
dc.rights.accessrights	https://purl.org/coar/access_right/c_abf2
dc.rights.local	Acceso abierto	spa
dc.rights.uri	http://creativecommons.org/licenses/by-nc-sa/4.0/
dc.source.url	https://docs.google.com/spreadsheets/d/12UpwN3yP4ywxRtZ97XsScjI5vKbcMuKenr- 0QceO8qI/edit?usp=sharing
dc.subject	CAR-T
dc.subject	Sistemas de entrega
dc.subject	Inmunoterapia
dc.subject	Cáncer
dc.subject	Efectos adversos
dc.subject.ddc	615.19
dc.subject.keywords	CAR-T
dc.subject.keywords	Delivery systems
dc.subject.keywords	Immunotherapy
dc.subject.keywords	Cancer
dc.subject.keywords	Adverse effects
dc.title	Revisión bibliográfica de terapia CAR T: enfoque en los diferentes sistemas de entrega novedosos
dc.title.translated	Literature review of CAR T therapy: focus on Different novel delivery systems
dc.type.coar	https://purl.org/coar/resource_type/c_7a1f
dc.type.coarversion	https://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.driver	info:eu-repo/semantics/bachelorThesis
dc.type.hasversion	info:eu-repo/semantics/acceptedVersion
dc.type.local	Tesis/Trabajo de grado - Monografía - Pregrado